Company Profiles

driven by the PitchBook Platform

Igenica Biopharmaceuticals

Description

Developer of antibody based therapeutics for the treatment of cancer. The company focuses research on recombinant monoclonal antibodies (mAbs), which are considered to be one of the most promising immunologic approaches to therapy. It has developed two unique technology platforms that collectively offer a function-orientated screening strategy to systematically identify new tumor antigens and effective mAb drug candidates.

2008

Founded

PRIVATE

Status

11-50

Employees

Series F

Latest Deal Type

$5.95M

Latest Deal Amount

$80.5M

Total Amount Raised

Description

Developer of antibody based therapeutics for the treatment of cancer. The company focuses research on recombinant monoclonal antibodies (mAbs), which are considered to be one of the most promising immunologic approaches to therapy. It has developed two unique technology platforms that collectively offer a function-orientated screening strategy to systematically identify new tumor antigens and effective mAb drug candidates.

Website:

www.igenica.com

Formerly Known As

Igenica

Ownership Status

Privately held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Drug Discovery

Other Industries

Pharmaceuticals

Primary Office

863A Mitten Road Suite 100B2 Burlingame, CA 94010United States +1 (650) 231-4320
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore Igenica Biopharmaceuticals's full profile, request a free trial.

Igenica Biopharmaceuticals Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

Igenica Biopharmaceuticals Cap Table

Stock# of Shares
Authorized
Par ValueDividend Rate (%)Original
Issue Price
LiquidationLiquidation
Pref. Multiple
Conversion
Price
% Owned

Igenica Biopharmaceuticals Investors (4)

Request access
Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
Seat
Contact
Info
5AM VenturesVenture CapitalMinority000 0000000 0000
OrbiMedVenture CapitalMinority000 0000000 0000
The Column GroupVenture CapitalMinority000 0000000 0000
Third Rock VenturesVenture CapitalMinority000 0000000 0000
5AM Ventures Venture Capital
OrbiMed Venture Capital
The Column Group Venture Capital
Third Rock Ventures Venture Capital

Igenica Biopharmaceuticals Executive Team (7)

NameTitleBoard
Seat
Contact
Info
Hans HouteChief Financial Officer
John CelebiChief Business Officer & Senior Vice President
Thi-Sau Migone Ph.DChief Scientific Officer
Robert Schreiber Ph.DCo-Founder & Board Member
Randall Halcomb Ph.DVice President of Chemistry
Hans Houte Chief Financial Officer
John Celebi Chief Business Officer & Senior Vice President
Thi-Sau Migone Ph.D Chief Scientific Officer
Robert Schreiber Ph.D Co-Founder & Board Member
Randall Halcomb Ph.D Vice President of Chemistry

Igenica Biopharmaceuticals Board Members (5)

NameRepresentingRoleSinceContact
Info
Carl Gordon Ph.DOrbiMedBoard Member000 0000
David Goeddel Ph.DThe Column GroupChairman000 0000
Gwen Fyfe MDSelfBoard Member000 0000
John Diekman Ph.D5AM VenturesBoard Member000 0000
Mark Goldsmith Ph.DThird Rock VenturesBoard Member000 0000
Carl Gordon Ph.D Board Member OrbiMed
David Goeddel Ph.D Chairman The Column Group
Gwen Fyfe MD Board Member Self
John Diekman Ph.D Board Member 5AM Ventures
Mark Goldsmith Ph.D Board Member Third Rock Ventures
Request full access to PitchBook